Melatonin and dehydroepiandrosterone combination: does this treatment exert a synergistic effect during experimental Trypanosoma cruzi infection?
Previous studies showed that melatonin or dehydroepiandrosterone (DHEA) enhances the immune response against parasitic pathogens. The present study investigated the in vitro activity of melatonin combined with DHEA in a period of 24 hr during the course of in vivo T. cruzi infection. The in vitro activity of melatonin or DHEA alone, as well as together, were tested for the trypomastigote forms (doses ranging from 0.5 to 128 microm). In vitro, neither melatonin nor DHEA alone had any activity against trypomastigote forms, although when the highest concentration of combined melatonin and DHEA was used, it was active against the trypomastigote forms of the parasite. However, for this concentration, a quite toxicity on peritoneal macrophages was observed. For in vivo evaluation, male Wistar rats were infected with the Y strain of T. cruzi. They were orally treated with 10 mg/kg body weight/day of melatonin and subcutaneously with 40 mg/kg body weight/day of DHEA. Treatment with melatonin, DHEA and the association showed a significant reduction in the number of blood trypomastigotes during the acute phase of infection as compared to untreated animals (P < 0.05). A significant increase in the number of macrophages and nitric oxide (NO) concentrations were observed during the peak of parasitaemia with melatonin alone or combined with DHEA. However, with DHEA alone the highest concentration of NO was observed (P < 0.05). Moreover, DHEA treatment increased TNF-alpha levels during the infection (P < 0.05). These results show that melatonin, DHEA or the combination of both reduces parasitemia during the acute phase of infection. The combined action of both molecules did not exert a synergic action on the host's ability to fight infection, and it seems that among all treatments DHEA induces a more efficient immune response.
Kuehn
Christian C
CC
Laboratório de Parasitologia, Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto FCFRP-USP, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.
Rodrigues Oliveira
Luiz G
LG
Santos
Carla Domingues
CD
Ferreira
Daniele Silva
DS
Alonso Toldo
Míriam P
MP
de Albuquerque
Sérgio
S
do Prado
José Clóvis
JC
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D014355:Chagas Disease / Q000188:drug therapy*; D003687:Dehydroepiandrosterone / Q000627:therapeutic use*; D004338:Drug Combinations; D004357:Drug Synergism; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D008297:Male; D008550:Melatonin / Q000627:therapeutic use*; D018512:Parasitemia / Q000188:drug therapy; D051381:Rats; D017208:Rats, Wistar; D014349:Trypanosoma cruzi / Q000187:drug effects*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000276:Adjuvants, Immunologic; D000975:Antioxidants; D004338:Drug Combinations; D014409:Tumor Necrosis Factor-alpha; D003687:Dehydroepiandrosterone; D008550:Melatonin